Skip to content

Research on pain treatment of pancreatic and bile duct abnormalitiestreatment with MSC-CM

Research on treatment of pain of pancreatic biliary confluence disorders with human-derived mesenchymal stem cells conditioned medium

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1051240232
Enrollment
Unknown
Registered
2025-01-06
Start date
2024-04-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain associated with pancreaticobiliary maljunction cholangitis

Interventions

None listed

Sponsors

Takigawa Shingo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who did not have a satisfactory therapeutic effect with standard treatment 2. Patients who do not wish to be treated with the drugs used in standard treatment due to concerns about side effects, etc., and those who have been judged by the doctor that chronic pain treatment with conditioned medium is optimal. Target patients who meet the following criteria. 1. 18 years old and over 2. Have normal consent ability 3. Patientse with a blood NT-proBNP level of 900 pg / mL or higher 4. Patients who can obtain their free will consent in writing 5. Patients whose doctor have recognized the need for treatment

Exclusion criteria

Exclusion criteria: Patient who meet any of the following conditions are excluded 1. Users of narcotics or stimulants 2. Judged unsuitable by the doctor

Design outcomes

Primary

MeasureTime frame
Improvement of subjective symptoms

Contacts

Public ContactIshiwata Yoshikazu

Kawagoe Chuou Cinic

y-ishiwata@kowakai-medical.or.jp+81-49-220-5500

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026